Changchun To Build Northeast China's Largest Vaccine R&D Base
This article was originally published in PharmAsia News
Executive SummaryChangchun city recently signed a strategic cooperation agreement with China Pharmaceutical Group, which was followed by another agreement involving the Changchun High-tech Development Area, the Changchun Institute of Biological Products, and Sinopharm Group
You may also be interested in...
As part of its response to the coronavirus outbreak, the European association representing generic and biosimilar drug companies, Medicines for Europe, has set out a series of policy recommendations that it says could help to mitigate the possible risks to medicines supply.
Podcast: Living In China's Coronavirus Lockdown, Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.